ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Limited (ASLN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
asln · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
ASLAN Pharmaceuticals LimitedYou ASLN | $777M | N/A | — | — |
 Albireo Pharma, Inc. ALBO | $916M | N/A | — | -$7.87 |
 Avid Bioservices, Inc. CDMO | $799M | N/A | — | -$2.23 |
 Chimerix, Inc. CMRX | $801M | N/A | — | -$0.99 |
 Exscientia plc EXAI | $633M | N/A | — | -$1.18 |
 Harpoon Therapeutics, Inc. HARP | $865M | N/A | — | -$20.24 |
 Intercept Pharmaceuticals, Inc. ICPT | $795M | 3.63x | — | $3.41 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for ASLAN Pharmaceuticals Limited (ASLN) measures how much investors pay for each dollar of the company's trailing earnings. ASLN's current PE ratio of N/A is calculated by dividing its stock price of $0.60 by its TTM earnings per share of —.
Frequently asked questions
ASLN pe ratio · 6 questionsASLN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.60 and TTM EPS of —. Data sourced from Financial Modeling Prep via ASLN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · ASLAN Pharmaceuticals Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09